Anti-Müllerian Hormone and Embryo Aneuploidy

Serum Anti-Müllerian Hormone Levels and Its Association With Aneuploidy Rates in Human Blastocysts

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05723016

Enrollment

300

Registered

2023-02-10

Start date

2018-01-01

Completion date

2022-12-31

Last updated

2023-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneuploidy, Infertility

Keywords

AMH, IVF, Aneuploidy, PGT-a, anti-mullerian hormone, oocyte quality

Brief summary

The goal of this observational study is to determine is there an association between the rates of aneuploidy and the different ranges of serum Antimullerian hormone (AMH) levels. Retrospective, single-centre study of patients undergoing IVF and preimplantation genetic testing with aneuploidy at the blastocyst stage between January 2018 and December 2022.

Interventions

OTHERpreimplantation genetic test for aneuploidies (PGT-a)

preimplantation genetic test for embryo aneuploidies after IVF

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* All started cycles planned to be followed by preimplantation genetic testing for aneuploidies (PGT-A). PGT-A is proposed to the couples for the following reasons: advanced maternal age, recurrent miscarriage, repeated implantation failure or severe male infertility factor; it is also offered to all patients with a good prognosis who desired information regarding the ploidy status of their embryos.

Exclusion criteria

* Data from oocyte donation cycles

Design outcomes

Primary

Measure	Time frame
Aneuplody rate	4 years

Secondary

Measure	Time frame
Clinical pregnancy rate	4 years
Miscarriage rate	4 years

Countries

Chile

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026